
usd feb pm et
summari danah corpor design manufactur market profession medic industri
commerci product servic global
price-to-earnings oper ep
risk assess reflect modest growth prospect
compani market good corpor
leadership solid balanc sheet compani
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb stock trade
expect dhr sale grow
includ impact
anticip acquisit
biopharma busi call cytiva
deal close anticip
core revenu growth follow
core growth
respect sale growth biopharma
busi acceler
posit view dhr acquisit ge
biopharma busi immens size
acquisit could prove challeng
drive higher revenu ep growth
invest higher-technolog
busi new geograph market
boost dhr growth potenti
spin-off weak margin
revenu
complet divest decemb
expect continu ebitda margin
improv driven dhr recent portfolio
manag activ look ebitda
margin
find share trade
forward earn near fair valu
consist free cash flow gener due
high recur revenu strong balanc
sheet support like continu
support abil make acquisit
key compon growth recent
year find manag
experienc make integr
acquisit compani suffer
margin degrad recent year
taken mani charg relat acquisit
risk recommend target price
includ difficulti ge biopharma
acquisit failur integr acquisit
unfavor foreign exchang slowdown
biopharmaceut develop
target base
ep estim
averag forward multipl
increas exposur
high margin product pend
acquisit significantli
lower-than-expect financ cost said
acquisit expect ge
biopharma busi contribut
apr ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview danah corpor design manufactur market profession
medic industri commerci product servic research develop manufactur
sale distribut servic administr facil locat countri
approxim sale deriv custom outsid busi broken
four segment life scienc revenu diagnost dental
life scienc offer broad rang research tool scientist use studi basic build block
life includ gene protein metabolit cell order understand caus diseas
identifi new therapi test new drug vaccin segment pall corpor pall
busi also lead provid filtrat separ purif technolog
biopharmaceut food beverag medic aerospac microelectron gener industri
sector sale segment geograph destin north america
europ develop market high-growth market
diagnost segment offer analyt instrument reagent consum softwar servic
hospit physician offic refer laboratori critic care set use diagnos
diseas make treatment decis sale segment geograph destin
north america western europ develop market high-growth market
compani dental segment provid product use diagnos treat prevent diseas
ailment teeth gum support bone well improv aesthet human
smile compani lead world-wide provid broad rang dental consum equip
servic dedic drive technolog innov help dental profession improv
clinic outcom enhanc product sale segment geograph destin
north america western europ develop market high-growth market
compani environment appli solut segment offer product servic help protect
import resourc keep global food water suppli safe sale segment
geograph destin north america western europ develop market
high-growth market
corpor strategi compani seek expand revenu combin intern growth
acquisit compani histori success acquisit expect compani
remain acquisit balanc sheet cash flow support activ
impact major develop gener electr agre sell biotechnolog busi ge
biopharma billion cash februari elimin major competitor
strong track record buy integr busi immens size
acquisit could prove challeng ge biopharma lead provid instrument consum
softwar support research discoveri process develop manufactur workflow
biopharmaceut drug anticip gener billion sale
expect transact close acquir busi stand-alon
oper compani life scienc segment
septemb spun-off dental busi revenu name
envista trade publicli ticker nyse septemb own
april close billion acquisit supplier custom nucleic
acid acquir ten busi total consider million cash net cash
acquir acquir cepheid lead global molecular diagnost compani total
purchas price approxim billion seven busi total consider
million cash net cash acquir
august acquir pall corp pll billion conjunct purchas
announc plan split two separ publicly-trad compani first maintain
name would combin pll life scienc filtrat busi second name
would includ industri busi includ test measur spun
sharehold juli sharehold receiv one share share
financi trend revenu grew year-over-year billion growth
partial driven acquisit year revenu growth continu oper
improv achiev dhr five-year compound annual growth rate
compound-annual-growth-rate ep free cash flow defin cash flow oper less capit
expenditur remain steadi last sever year increas
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc novemb technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
next month neutral expect
compani continu achiev robust organ
growth mid- high-single-digit revenu
growth driven new product
data provid estim world-wide medic
devic sale grow
time think potenti slowdown
macroeconom growth could pressur
industri driver yet sub-industri
includ mani product area
histor recession-resist
equip use non-elect procedur
gener see posit long-term
fundament medic devic manufactur
includ increas global demand
popul rise outlay
result steadi flow innov product
revenu growth
polit regulatori perspect
medic devic industri larg avoid
scrutini unlik area health
drug maker fact medic devic tax
final repeal decemb remov
signific risk sale devic maker
think industri continu
dwindl industri come back
favor especi sinc valuat health
rel
forward price-to-earn basi think
higher valuat sub-industri
mostli warrant margin expans
revenu growth opportun associ
 medic devic regul
mdr go effect may
follow vitro devic
regul ivdr goe effect
devic compani made much
commentari around introduct mdr
reason believ new
regul could neg impact
industri exampl juli
submit letter world trade
organ request mdr ivdr
delay three year also novemb
associ critic slow piecem
implement new regulatori
accord evalu
billion valu prior
five-year averag deal total
billion industri debt level measur
net debt rel total capit appear
declin substanti follow
sever year increas think
industri could see increas deal
especi new ceo sever
major firm
expect industri earn rise
low-double-digit percentag driven sale
new product command higher
margin project industri oper
ebit margin
estim margin
 health equip
valu composit index
 health equip
sub-index rose vs declin
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
becton dickinson compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
pm et cfra reiter hold opinion share danah corpor
lift price target base multipl
ep estim forward price-to-earnings
averag reflect strong momentum posit view today news
gener electr ge agre today sell biotechnolog busi ge
biopharma billion cash elimin major competitor
strong track record buy integr busi
immens size acquisit could prove challeng ge biopharma
lead provid instrument consum softwar support
research discoveri process develop manufactur workflow
biopharmaceut drug anticip gener
billion sale expect transact close
acquir busi stand-alon oper compani life
et cfra keep hold recommend share
rais target price valu
share ep estim well industri peer
forward price-to-earnings averag reflect strong momentum
posit view today news acquir ge biotechnolog
instrument divis billion cash think natur fit
exist busi elimin major competitor busi
creat wide moat gap competitor howev
think may challeng relat integr busi price
tag sale forward ebitda extrem expens
fantast track record buy integr busi
purchas complet differ scale share sharpli
pre-market news think upsid next may
mute like line overal market /kevin huang cfa
analyst research note compani news
pm et cfra maintain hold opinion share danah corpor
lift target price base
multipl ep estim increas multipl
reflect dhr increas exposur high margin product
pend acquisit significantli lower-than-expect
financ cost said acquisit ep vs came
consensu lower ep estim
initi ep sale increas organ
billion dhr high-growth market grew high
single-digit western europ sale grew mid-single-digit
continu expect busi acquir
expect acquisit contribut ep satisfi
regulatori requir soon divest certain life scienc busi
provid annual revenu approxim million /kevin huang
pm et cfra maintain hold opinion share danah corpor
lift target price base
multipl ep estim forward multipl
reflect compani increas exposur attract market ep
vs estim adjust ep
ep sale increas
organ billion organ revenu growth life scienc
segment diagnost environment believ
share trade slightli today compani weaker-than-expect
guidanc core revenu growth remind complet
ipo dental busi envista nr mid-septemb
end own also anticip
acquisit complet rather ge
biopharma busi call cytiva becom part /kevin
pm et cfra maintain hold opinion share danah corpor
lift target price base
multipl ep estim multipl
significantli histor forward multipl compani
increas exposur attract market ep vs
consensu estim rais ep
ep estim sale increas organ
billion organ revenu growth life scienc segment
diagnost dental environment spite
concern slow econom growth china manag confid
underli condit sale china grew year-over-year
quarter addit upcom ipo dental busi
anticip merger aim
close remain track dental busi call envista /kevin
et cfra keep hold opinion share danah corpor
lift target base multipl
ep estim multipl
three-year averag forward multipl compani
increas exposur attract market ep vs
lower estim lower ep
reflect impact recent equiti offer associ
in-progress ge biopharma acquisit lift ep
sale increas organ billion organ revenu
growth life scienc segment diagnost dental
environment despit concern around china trade tension
slowdown chines economi achiev ninth consecut quarter
double-digit growth china growth across four segment
manag appear much concern stabil
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
